Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Mitchell Mcleod Pugh & Williams Inc.

Mitchell Mcleod Pugh & Williams Inc. boosted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 503 shares of the medical equipment provider’s stock after acquiring an additional 20 shares during the period. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Intuitive Surgical were worth $247,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in ISRG. International Assets Investment Management LLC grew its stake in Intuitive Surgical by 49,383.6% in the 3rd quarter. International Assets Investment Management LLC now owns 1,090,619 shares of the medical equipment provider’s stock valued at $535,788,000 after acquiring an additional 1,088,415 shares during the last quarter. Capital Research Global Investors acquired a new stake in shares of Intuitive Surgical during the 1st quarter worth about $374,390,000. Vanguard Group Inc. boosted its stake in shares of Intuitive Surgical by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after purchasing an additional 493,126 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Intuitive Surgical by 51.2% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock worth $356,524,000 after purchasing an additional 302,382 shares during the last quarter. Finally, Strategic Financial Concepts LLC boosted its stake in shares of Intuitive Surgical by 40,221.4% during the 2nd quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock worth $1,184,000 after purchasing an additional 265,461 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on ISRG. Oppenheimer reaffirmed a “market perform” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. Barclays increased their price objective on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Citigroup increased their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Stifel Nicolaus increased their price objective on shares of Intuitive Surgical from $475.00 to $525.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Finally, BTIG Research set a $535.00 price target on shares of Intuitive Surgical in a report on Friday, October 18th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $513.74.

Intuitive Surgical Price Performance

ISRG traded up $12.17 during trading on Friday, hitting $536.45. The company had a trading volume of 1,427,803 shares, compared to its average volume of 1,307,284. The company has a market cap of $191.07 billion, a PE ratio of 86.25, a P/E/G ratio of 5.07 and a beta of 1.39. The business has a 50-day moving average of $493.92 and a 200-day moving average of $451.73. Intuitive Surgical, Inc. has a 1-year low of $269.49 and a 1-year high of $538.49.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.32. The firm had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. Research analysts forecast that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current year.

Insider Activity at Intuitive Surgical

In related news, EVP Robert Desantis sold 240 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $464.76, for a total value of $111,542.40. Following the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,558,968.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Intuitive Surgical news, EVP Robert Desantis sold 240 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $464.76, for a total transaction of $111,542.40. Following the completion of the sale, the executive vice president now owns 5,506 shares in the company, valued at $2,558,968.56. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,246 shares of company stock valued at $33,839,308 over the last ninety days. Corporate insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.